Top 10 AI-Powered Biotech Stocks to Buy Now

2. AbbVie Inc. (NYSE:ABBV)

Number Of Hedge Fund Holders: 89

AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical leader known for therapies across immunology, oncology, and neuroscience, recently secured a major development for its immunology portfolio. On September 11, 2025, the company announced a settlement with all generic manufacturers challenging Rinvoq (upadacitinib), extending its U.S. patent protection and exclusivity until 2037. This extension delays generic competition by about four years and is expected to help sustain Rinvoq’s blockbuster sales, which reached nearly $6 billion in 2024, supporting the firm’s transition as Humira revenues decline.

Rinvoq, approved for rheumatoid arthritis and multiple autoimmune disorders, is also undergoing clinical trials for additional indications such as alopecia areata, vitiligo, hidradenitis suppurativa, and systemic lupus erythematosus. This broad pipeline reflects AbbVie Inc. (NYSE:ABBV)’s strategic focus on expanding its immunology franchise and delivering next-generation therapies to underserved patient populations.

The corporation leverages AI and data analytics to support its drug development and pipeline management. AI-driven insights help optimize patient selection, accelerate clinical trials, and enhance treatment outcomes, although specific projects were not highlighted in recent news. Complementing this innovation, the company announced a $195 million expansion of its active pharmaceutical ingredient manufacturing facilities in mid-2025, strengthening its biotechnology and production capabilities.

With patent protection secured and a robust pipeline enhanced by AI-powered insights, AbbVie Inc. (NYSE:ABBV) positions itself for continued growth in immunology while maintaining momentum across its broader therapeutic portfolio.